The U.S. Food and Drug Administration (FDA) announced this week that it is requiring manufacturers of all GLP-1 diabetes and obesity medications to make labeling changes that will warn patients about the increased risk of a rare eye condition linked to these drugs.e60dc2a1-f33c-4a05-9b50-8e3e8e5976298816fb5d-d5cf-45cb-8995-6136a948e86f The condition, called non-arteritic anterior ischemic optic neuropathy or NAION, occurs when blood flow to the optic nerve is blocked, causing sudden, painless loss of vision in one eye. It is often referred to as "eye stroke," and vision loss can be…
Read the full article at EVERYDAYHEALTH.COM